A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus

Clin Endocrinol (Oxf). 2012 Oct;77(4):635-7. doi: 10.1111/j.1365-2265.2012.04368.x.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Exenatide
  • Female
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Obesity / drug therapy*
  • Obesity / metabolism
  • Peptides / therapeutic use
  • Receptors, Glucagon / agonists*
  • Receptors, Glucagon / metabolism*
  • Venoms / therapeutic use

Substances

  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Peptides
  • Receptors, Glucagon
  • Venoms
  • Exenatide